FDA clears lifesaving device that can plug bullet wounds in seconds

FDA Approves Device to Stop Bleeding from Gunshot Wounds in 15 Seconds
The FDA has cleared a lifesaving military device for civilian use. The XSTAT 30 created by RevMedX is expandable, multi-sponge filled syringe used to control life-threatening bullet wounds. It has been in use by the military since April 2014.

SEE ALSO: New report reveals states fail to sufficiently fund tobacco prevention

The device contains 92 tablet-sized sponges that expand upon contact with blood. The syringe can stop bleeding within 15 seconds allowing the injured to be rushed to the hospital without hemorrhaging.

A FDA press release notes that according to the United States Army Institute of Surgical Research, 30 to 40 percent of civilian deaths by traumatic injury are the result of hemorrhaging and 33 to 56 percent of those deaths occur before the patient reaches a hospital.

"When a product is developed for use in the battlefield, it is generally intended to work in a worst-case scenario where advanced care might not be immediately available," said William Maisel, M.D., M.P.H., acting director of the Office of Device Evaluation in the FDA's Center for Devices and Radiological Health. "It is exciting to see this technology transition to help civilian first responders control some severe, life-threatening bleeding while on the trauma scene."

Although the device has been cleared for civilian use, the XSTAT 30 is to only be used in patients at high risk for immediate, life-threatening, and severe hemorrhagic shock when care at an emergency care facility cannot be quickly achieved.

Here's more on the XSTAT 30​:
FDA Approves Syringe To Plug Gunshot Wounds
More on the FDA:
FDA issues warning letters to powdered caffeine distributors
FDA approves female sex pill, but with safety restrictions
FDA recalls popular brand of dog bones for salmonella contamination
Read Full Story

Sign up for Breaking News by AOL to get the latest breaking news alerts and updates delivered straight to your inbox.

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.